Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu ...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patie ...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

Fortrea forecasts revenue and EBITDA declines for 2025. With a $477.16M market cap, financial improvement could drive stock ...

Tokyo Electron is in a fairly strong financial position. The company has no debt and typically maintains a substantial cash position on its balance sheet, which we believe is appropriate for chip ...

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified ...

In an effort to offer customers better service, the United States Patent and Trademark Office has been modernizing various ...

Learn how AI in drug discovery is revolutionizing therapeutic development and addressing challenges in cell and gene therapy.

Explore the impact of 3D models in drug discovery and how they enhance predictive insights in pre-clinical research.

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...